BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24115356)

  • 1. Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.
    Mani T; Liu D; Zhou D; Li L; Knabe WE; Wang F; Oh K; Meroueh SO
    ChemMedChem; 2013 Dec; 8(12):1963-77. PubMed ID: 24115356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion.
    Khanna M; Wang F; Jo I; Knabe WE; Wilson SM; Li L; Bum-Erdene K; Li J; W Sledge G; Khanna R; Meroueh SO
    ACS Chem Biol; 2011 Nov; 6(11):1232-43. PubMed ID: 21875078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction.
    Liu D; Xu D; Liu M; Knabe WE; Yuan C; Zhou D; Huang M; Meroueh SO
    Biochemistry; 2017 Mar; 56(12):1768-1784. PubMed ID: 28186725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.
    Rea VE; Lavecchia A; Di Giovanni C; Rossi FW; Gorrasi A; Pesapane A; de Paulis A; Ragno P; Montuori N
    Mol Cancer Ther; 2013 Aug; 12(8):1402-16. PubMed ID: 23699658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.
    Mani T; Wang F; Knabe WE; Sinn AL; Khanna M; Jo I; Sandusky GE; Sledge GW; Jones DR; Khanna R; Pollok KE; Meroueh SO
    Bioorg Med Chem; 2013 Apr; 21(7):2145-55. PubMed ID: 23411397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.
    Wang F; Li J; Sinn AL; Knabe WE; Khanna M; Jo I; Silver JM; Oh K; Li L; Sandusky GE; Sledge GW; Nakshatri H; Jones DR; Pollok KE; Meroueh SO
    J Med Chem; 2011 Oct; 54(20):7193-205. PubMed ID: 21851064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
    Duriseti S; Goetz DH; Hostetter DR; LeBeau AM; Wei Y; Craik CS
    J Biol Chem; 2010 Aug; 285(35):26878-26888. PubMed ID: 20501655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mimicking Intermolecular Interactions of Tight Protein-Protein Complexes for Small-Molecule Antagonists.
    Xu D; Bum-Erdene K; Si Y; Zhou D; Ghozayel MK; Meroueh SO
    ChemMedChem; 2017 Nov; 12(21):1794-1809. PubMed ID: 28960868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGF stimulates uPAR expression and cell invasiveness through ERK, AP-1, and NF-kappaB signaling in human gastric carcinoma cells.
    Baek MK; Kim MH; Jang HJ; Park JS; Chung IJ; Shin BA; Ahn BW; Jung YD
    Oncol Rep; 2008 Dec; 20(6):1569-75. PubMed ID: 19020743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide.
    Gargiulo L; Longanesi-Cattani I; Bifulco K; Franco P; Raiola R; Campiglia P; Grieco P; Peluso G; Stoppelli MP; Carriero MV
    J Biol Chem; 2005 Jul; 280(26):25225-32. PubMed ID: 15866865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
    Bessard A; Frémin C; Ezan F; Coutant A; Baffet G
    J Cell Physiol; 2007 Aug; 212(2):526-36. PubMed ID: 17427199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-Molecule Inhibition of the uPAR ⋅ uPA Interaction by Conformational Selection.
    Xu D; Bum-Erdene K; Leth JM; Ghozayel MK; Ploug M; Meroueh SO
    ChemMedChem; 2021 Jan; 16(2):377-387. PubMed ID: 33107192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cadmium induces urokinase-type plasminogen activator receptor expression and the cell invasiveness of human gastric cancer cells via the ERK-1/2, NF-κB, and AP-1 signaling pathways.
    Khoi PN; Xia Y; Lian S; Kim HD; Kim DH; Joo YE; Chay KO; Kim KK; Jung YD
    Int J Oncol; 2014 Oct; 45(4):1760-8. PubMed ID: 25069788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
    Mauro CD; Pesapane A; Formisano L; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Monteleone F; Zambrano N; Fontanini G; Servadio A; Pignataro G; Grumetto L; Lavecchia A; Bruzzese D; Iaccarino A; Troncone G; Veneziani BM; Montuori N; Placido S; Bianco R
    Sci Rep; 2017 Aug; 7(1):9388. PubMed ID: 28839232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
    Besch R; Berking C; Kammerbauer C; Degitz K
    Cell Death Differ; 2007 Apr; 14(4):818-29. PubMed ID: 17110957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.